Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer

Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer

Abstract Background The trastuzumab, pertuzumab, and docetaxel (TPD) regimen is strongly recommended as a treatment option for first-line therapy for advanced human epidermal growth factor receptor (HER) 2-positive breast cancer. Monitoring the host microenvironments in cancer plays a significant ro...

Full description

Bibliographic Details
Main Authors: Koji Takada, Shinichiro Kashiwagi, Wataru Goto, Yuka Asano, Katsuyuki Takahashi, Tsutomu Takashima, Shuhei Tomita, Masahiko Ohsawa, Kosei Hirakawa, Masaichi Ohira
Format: Article
Language:English
Published: BMC 2018-04-01
Series:Journal of Translational Medicine
Subjects:
Tumor-infiltrating lymphocytes
Breast cancer
Pertuzumab
HER2
CD8/FOXP3 ratio
Online Access:http://link.springer.com/article/10.1186/s12967-018-1460-4

Internet

http://link.springer.com/article/10.1186/s12967-018-1460-4

Similar Items